B2M and glioma: Considering the existence of the blood‐brain barrier in the central nervous system, we conclude that the combined detection of B2M levels in tumor tissues, cerebrospinal fluid, and serum might enable optimal specificity for the diagnoses of different molecular subtypes and clinical stages of gliomas.